Daratumumab Pilot Study Offers New Insights into ME/CFS

A new pilot study has added to the growing evidence that the immune system may play an important role in ME/CFS for some patients. Researchers investigated daratumumab, a medication that targets long-lived plasma cells, the immune cells responsible for producing antibodies. Their hypothesis is that, in a subgroup of people with ME/CFS, these plasma cells may produce harmful autoantibodies that…